Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- AnGes MG Eyes PIII Trial for Collategene in US, Europe by 2013-End
May 8, 2013
- Nichi-Iko Voluntarily Recalls Enalapril Maleate Tablets
May 7, 2013
- BI Japan’s Ethical Drug Sales Up 7.3% with Prazaxa Sales of 23.5 Billion Yen
May 7, 2013
- Fujifilm Kyowa Kirin Biologics Looking for Marketing Partners in Europe and US: Executive VP Kawaguchi
May 7, 2013
- Mochida Files NDA for PAH Treatment Treprostinil
May 7, 2013
- Daiichi Sankyo, Perosphere to Develop Anticoagulant Reversal Agent for Edoxaban
May 2, 2013
- Anticancer Agent Xtandi Receives Positive Opinion for Marketing Approval by EMA: Astellas
May 2, 2013
- Boehringer to Enter Oncology Market, Hire 100 MRs in Japan
May 2, 2013
- Boehringer Chief Says Japan Business Successful
May 2, 2013
- Astellas Vice President Miyokawa to Be Promoted to Representative Director
May 2, 2013
- Novartis Investigating Employee Involvement in Retracted Diovan Papers
May 1, 2013
- Torii Aims for Sales of 63 Billion Yen in FY2015, Expanding Allergen Field
May 1, 2013
- Torii to Launch Anti-HIV Drug Stribild Combination Tablets on May 14
May 1, 2013
- Eisai to Establish New Parenteral Plant to Manufacture Methycobal in China
May 1, 2013
- With Mucosta Pursuing Diquas, New Drugs Have Growing Presence in Market for Dry Eye Treatments
April 30, 2013
- UMN to Open Japan’s Biggest Biopharmaceutical Contract Manufacturing Facility; Success or Failure Could Determine the Future of this Business in Japan
April 30, 2013
- Ethical Drug Production to Exceed 12 Trillion Yen in 2020: Yano Research Institute
April 30, 2013
- Sandoz K.K. Applies for Gran Biosimilar
April 26, 2013
- Daiichi Sankyo Begins Nimotuzumab PIII Trials for Lung and Gastric Cancers
April 26, 2013
- Boehringer Filed NDA for Afatinib in Japan: Chairman
April 26, 2013
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…